Sugi Predict

Sugi Predict / Targets / GALR1

GALR1

Galanin receptor type 1 · P47211 · GALR1 on Sugi Atlas →

5,380 patent compounds predicted against GALR1, 2,367 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL412844 SCHEMBL412844 1.00 20/20
SCHEMBL3237771 SCHEMBL3237771 0.54 10/20
SCHEMBL3240927 SCHEMBL3240927 0.77 9/20
SCHEMBL3240515 SCHEMBL3240515 0.64 9/20
SCHEMBL3240980 SCHEMBL3240980 0.62 9/20
SCHEMBL3240588 SCHEMBL3240588 0.59 9/20
SCHEMBL3241078 SCHEMBL3241078 0.57 9/20
SCHEMBL3266094 SCHEMBL3266094 0.55 9/20
SCHEMBL3244045 SCHEMBL3244045 0.54 9/20
SCHEMBL3451519 SCHEMBL3451519 0.63 8/20
SCHEMBL3241392 SCHEMBL3241392 0.59 8/20
SCHEMBL3450563 SCHEMBL3450563 0.58 8/20
SCHEMBL4829509 SCHEMBL4829509 0.57 8/20
SCHEMBL3240907 SCHEMBL3240907 0.57 8/20
SCHEMBL3450914 SCHEMBL3450914 0.56 8/20
SCHEMBL3245976 SCHEMBL3245976 0.56 8/20
SCHEMBL3235553 SCHEMBL3235553 0.55 8/20
SCHEMBL2177922 SCHEMBL2177922 0.51 8/20
SCHEMBL3246372 SCHEMBL3246372 0.58 7/20
SCHEMBL3451772 SCHEMBL3451772 0.56 7/20

Clinical trials — most relevant to GALR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration PHASE4COMPLETED
Medication, Weight Gain and GI Hormones PHASE4COMPLETED
Galantamine for Cognition in People With Schizophrenia PHASE4COMPLETED
Oliceridine in Patients With Acute Burn Injuries PHASE4COMPLETED
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep PHASE3COMPLETED
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA) PHASE3COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma PHASE2RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers PHASE2COMPLETED
Vaccine Treatment for Surgically Resected Pancreatic Cancer PHASE1/PHASE2COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY PHASE1COMPLETED
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY PHASE1COMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment nanNOT_YET_RECRUITING
A Wearable Device and AI-Supported Diet and Exercise Intervention nanRECRUITING
Auricular Vagus Stimulation in Obesity nanACTIVE_NOT_RECRUITING
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors nanCOMPLETED
Efficacy of an Intravaginal Treatment With Carboxymethyl-β-glucan and Polycarbophil in HR-HPV Clearance nanUNKNOWN
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia nanUNKNOWN
The Role of Galectins in the Non-invasive Diagnosis of Endometriosis nanUNKNOWN
Association Study of Gene Polymorphisms With Cardiac Performance nanUNKNOWN
Brain Receptors in Sympathetic Nervous System Regulation nanCOMPLETED
Selective Activation of the Adrenomedullin Receptors in Migraine nanNOT_YET_RECRUITING
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing nanCOMPLETED
The Role of Autoantibodies Against G-protein Coupled Receptors in Obesity nanNOT_YET_RECRUITING
Acylated Ghrelin Response to Acute Exercise in Obesity nanCOMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease nanRECRUITING
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a GALR1 binder may also engage these)

ProteinNameSimilarity
P56479 — 0.999 P56479 →
Q62805 — 0.997 Q62805 →
P24053 — 0.953 P24053 →
NMBR Neuromedin-B receptor 0.951 landscape →
O54799 — 0.950 O54799 →
B2ZI34 — 0.947 B2ZI34 →
P35377 — 0.946 P35377 →
P33533 — 0.946 P33533 →
P35370 — 0.946 P35370 →
P32300 — 0.945 P32300 →
P41144 — 0.941 P41144 →
OPRD1 Delta-type opioid receptor 0.941 landscape →
OPRL1 Nociceptin receptor 0.940 landscape →
P79292 — 0.939 P79292 →
P83858 — 0.938 P83858 →
P83861 — 0.937 P83861 →
OPRK1 Kappa-type opioid receptor 0.936 landscape →
P42866 — 0.935 P42866 →
P47748 — 0.934 P47748 →
Q2KIP6 — 0.931 Q2KIP6 →
P33535 — 0.931 P33535 →
P34975 — 0.930 P34975 →
Q5IS39 — 0.930 Q5IS39 →
Q5IS84 — 0.929 Q5IS84 →
OPRM1 Mu-type opioid receptor 0.929 landscape →
P33534 — 0.929 P33534 →
QRFPR Pyroglutamylated RF-amide peptide receptor 0.927 landscape →
Q95M54 — 0.926 Q95M54 →
P79350 — 0.923 P79350 →
Q95247 — 0.920 Q95247 →